ODX.L Regulatory News (ODX)

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Directorate Change

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that Kieron Harbinson, Group Finance Director of the Company, has notified the Board that he will step down from his position after 19 years of service with the Company. The Board would like to thank Kieron for his many years of service and wish him all the luck his future endeavours.

Following a process to identify a replacement, the Company has agreed to appoint Chris Lea, ACA, as Chief Financial Officer. Chris is an experienced public markets CFO, having most recently held the position of Chief Financial Officer at IndigoVision Group plc (AIM: IND) and Finance Director at Superglass Holdings PLC (AIM: SPGH) before that.

Chris qualified as a chartered accountant with KPMG in 1992 and has extensive public company and private equity board level experience gained within multi-national, high growth and turnaround environments. Chris' appointment will be effective as of 30 August 2021.

Colin King, Chief Executive Officer of the Company, said: 

"I would like to personally thank Kieron for all the support and guidance he has provided me since I joined the Company, he has been a great servant to Omega and I wish him all the best in whatever he decides to do in the future. I would also like to welcome Chris Lea to Omega next month and look forward to working with him on the next phase of Omega's exciting future"

The following information is disclosed about Christopher Paul Lea, age 54, pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

Mr. Lea does not currently hold any ordinary shares in the Company. There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Contacts: